Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
28.39
-0.49 (-1.70%)
At close: Mar 5, 2026, 4:00 PM EST
28.39
0.00 (0.00%)
After-hours: Mar 5, 2026, 4:57 PM EST
Edgewise Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Edgewise Therapeutics stock have an average target of 36, with a low estimate of 14 and a high estimate of 51. The average target predicts an increase of 26.81% from the current stock price of 28.39.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Edgewise Therapeutics stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 3 | 3 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $30 → $45 | Buy | Maintains | $30 → $45 | +58.51% | Feb 27, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $33 → $34 | Buy | Maintains | $33 → $34 | +19.76% | Nov 14, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $49 → $50 | Buy | Maintains | $49 → $50 | +76.12% | Nov 7, 2025 |
| Wedbush | Wedbush | Buy Maintains $35 → $32 | Buy | Maintains | $35 → $32 | +12.72% | Nov 7, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Initiates $20 | Hold | Initiates | $20 | -29.55% | Sep 25, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
16.26M
EPS This Year
-2.15
from -1.63
EPS Next Year
-2.41
from -2.15
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | 53.2M | |||
| Avg | n/a | 16.3M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.79 | -1.75 | |||
| Avg | -2.15 | -2.41 | |||
| Low | -2.43 | -3.26 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.